Pratik Shah, Ph.D., is the current CEO of Design Therapeutics, Inc., having stepped into this role in August 2023 after serving as Executive Chair since 2017. His educational background is solid, with a Bachelor's degree in Biological Sciences from UC...

Pratik Shah, Ph.D., is the current CEO of Design Therapeutics, Inc., having stepped into this role in August 2023 after serving as Executive Chair since 2017. His educational background is solid, with a Bachelor's degree in Biological Sciences from UC Irvine and both a Ph.D. in Biochemistry and an MBA from the University of Chicago. Dr. Shah has extensive experience in the biopharmaceutical industry, including key positions at ARS Pharmaceuticals and Auspex Pharmaceuticals, where he led the company during its acquisition by Teva Pharmaceuticals. In 2023, his total compensation was reported at $560,352, which includes a salary of $360,600 and a bonus of $181,552. Dr. Shah is known for his strategic vision and ability to navigate complex research and development, as shown by the company's performance metrics. He has a history of significant insider trading activity, peaking with trades valued at over $91 million in early 2024, reflecting confidence in the stock. Pratik's leadership reflects a blend of scientific knowledge and business acumen, which is critical for steering the company in the competitive biotech landscape.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Design Therapeutics, Inc. CEOs

D

Pratik Shah, Ph.D.

CEO of Design Therapeutics, Inc.

Education

B.S. in Biological Sciences from the University of California at Irvine; Ph.D. in Biochemistry and Molecular Biology and M.B.A. in Finance from the University of Chicago.

Field of Expertise

Healthcare & Life Sciences - Biochemistry

Sector of Economy

Healthcare

CEO of Design Therapeutics, Inc. for

1 year 8 months (Aug 2023 - Present)

Previous Experience

Chairman of the board of directors for ARS Pharmaceuticals, Inc.; President of Marlinspike Group, LLC; Chairman of the board of directors of Synthorx, Inc.; President and Chief Executive Officer of Auspex Pharmaceuticals, Inc.; Partner at Thomas, McNerney & Partners.

Rivals

Competitors/colleagues of Pratik Shah, Ph.D.

Holdings

See how much did Pratik Shah, Ph.D. make over time.

Dr. Pratik Shah’s holdings in Design Therapeutics highlight his deep financial investment in the company. As of March 2024, he owned approximately 459,298 shares, which signifies his commitment as a stakeholder. His shares previously included various transactions that showcased fluctuations...

Dr. Pratik Shah’s holdings in Design Therapeutics highlight his deep financial investment in the company. As of March 2024, he owned approximately 459,298 shares, which signifies his commitment as a stakeholder. His shares previously included various transactions that showcased fluctuations in his wealth over time, particularly leading up to 2024 when his net worth tied closely to the company's performance. Notably, he has traded up to $92 million in stock value between 2023 and early 2024, indicating significant confidence and anticipation in Design Therapeutics' future. Previously reported trades ranged from $1.81 million to over $82 million in the months leading up to his current role, suggesting an ongoing strategy to align his personal financial interests with the company’s growth and success.

Mar 11, 2025

D

shares

DSGN @ $5.09

S

shares

SPRY @ $11.37

Charitable Transactions

SPRY

3,998,750 shares

SPRY

Recent Charitable Transactions

SPRY

1,332,900 shares

SPRY

Jun 13, 2024

Charity

SPRY

1,332,950 shares

SPRY

Jun 7, 2024

Charity

SPRY

1,332,900 shares

SPRY

Jun 4, 2024

Charity

Insider Trading

See recent insider trades of Pratik Shah, Ph.D..

SPRY

1,332,900 shares

SPRY

Jun 13, 2024

Charity

SPRY

1,332,950 shares

SPRY

Jun 7, 2024

Charity

SPRY

1,332,900 shares

SPRY

Jun 4, 2024

Charity

SPRY

1,332,900 shares

SPRY

Jun 4, 2024

Charity

SPRY

10,156,204 shares

SPRY

Nov 8, 2022

Received

DSGN

$500.00K

DSGN at $20.00/share

Mar 30, 2021

Purchase

Compensation History

See how much did Pratik Shah, Ph.D. make over time.

In 2023, Pratik Shah's total compensation was $560,352, including a base salary of $360,600 and a discretionary cash bonus of $181,552. This reflects not only his leadership role but also the company's growth in the competitive biopharmaceutical market. The compensation package aims to retain talent and is aligned with company performance, indicating that a portion of his pay is linked to the success he drives at Design Therapeutics. The bonus received in 2023 was a reward for contributions in the recent years, underscoring his influence in guiding research and development initiatives.

Year

2023

Total Compensation

$555.35K

Salary

$360.60K

Board Justification

The compensation philosophy aligns with company performance, peer benchmarking, and retention strategies, focusing on attracting and retaining top talent in the biopharmaceutical industry.

Bonus

$181.55K

Board Justification

Amount represents a discretionary cash bonus paid to Dr. Shah for his contributions to the Company in 2022 and 2023.

Other

$13.20K

Board Justification

Consists of matching contributions to the 401(k) plan.

Restricted Stock

$0.00(0 common stock)

Board Justification

No stock was reported as vested in 2023.

Performance Metrics

Performance metrics for 2023 included research and development, pipeline, and operating objectives.

Other Design Therapeutics, Inc. CEOs

Here are other CEOs of Design Therapeutics, Inc.

João Siffert, M.D.

Ex-CEO of Design Therapeutics, Inc.

June 2021 - August 2023